Paul Segal, chairman and co-founder of Symtomax, details what the most common myths about CBD are. Medicinal cannabis is by no means a new phenomenon. On the contrary, the cannabis plant has been used as a form of pain relief for thousands of years. However, it has only been within the past decade that modern consumers, and indeed some medical professionals, have begun to recognise its possible benefits – particularly ...
Read More

Symtomax have recently concluded the design and integration of their propagation houses with leading company AgroPharm that specialises in advanced solutions for the pharmaceutical medical cannabis industry. The designs which were submitted back in 2019 are based on the number of plants per cycle (45.000)
The greenhouses will be utilised for the germination in our first stages of growing but can also be used in the vegetative stages for ...
Read More

Symtomax has created its very own CBD oral tab as a novel and innovative delivery form for cannabinoids. Over the last few years the global market for cannabidiol (CBD) has expanded rapidly with growing demand for CBD products expected to continue through 2022 – transforming this market into a mega industry of its own. According to the latest research by the Global Wellness Institute (GWI), the worldwide wellness market grew 12.9% from ...
Read More

Discover how the Porto based medical cannabis company, Symtomax, is poised to conquer the European market and beyond. Symtomax based in Porto, Portugal are licenced to cultivate, import and export medical cannabis SativaL, with their facility that includes indoor, outdoor and greenhouse cultivation, research and quality control labs as well as processing, packaging and distribution for medical cannabis and cannabinoid-containing products, totalling 105 hectares with 95 hectares approved for cultivation ...
Read More